JP2021519600A - 抗原性インフルエンザ−フェリチンポリペプチド - Google Patents

抗原性インフルエンザ−フェリチンポリペプチド Download PDF

Info

Publication number
JP2021519600A
JP2021519600A JP2020554536A JP2020554536A JP2021519600A JP 2021519600 A JP2021519600 A JP 2021519600A JP 2020554536 A JP2020554536 A JP 2020554536A JP 2020554536 A JP2020554536 A JP 2020554536A JP 2021519600 A JP2021519600 A JP 2021519600A
Authority
JP
Japan
Prior art keywords
ferritin
influenza
polypeptide
antigenic
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020554536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519600A5 (https=
Inventor
ゲイリー・ジェイ・ナーベル
チィ−ジェン・ウェイ
レベッカ・ルディセル
ニコル・ダリカレレ
カート・スワンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2021519600A publication Critical patent/JP2021519600A/ja
Publication of JP2021519600A5 publication Critical patent/JP2021519600A5/ja
Priority to JP2024006461A priority Critical patent/JP2024041980A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020554536A 2018-04-03 2019-04-02 抗原性インフルエンザ−フェリチンポリペプチド Pending JP2021519600A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024006461A JP2024041980A (ja) 2018-04-03 2024-01-19 抗原性インフルエンザ－フェリチンポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652204P 2018-04-03 2018-04-03
US62/652,204 2018-04-03
PCT/US2019/025377 WO2019195284A1 (en) 2018-04-03 2019-04-02 Antigenic influenza-ferritin polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024006461A Division JP2024041980A (ja) 2018-04-03 2024-01-19 抗原性インフルエンザ－フェリチンポリペプチド

Publications (2)

Publication Number Publication Date
JP2021519600A true JP2021519600A (ja) 2021-08-12
JP2021519600A5 JP2021519600A5 (https=) 2022-04-07

Family

ID=66175544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554536A Pending JP2021519600A (ja) 2018-04-03 2019-04-02 抗原性インフルエンザ−フェリチンポリペプチド
JP2024006461A Pending JP2024041980A (ja) 2018-04-03 2024-01-19 抗原性インフルエンザ－フェリチンポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024006461A Pending JP2024041980A (ja) 2018-04-03 2024-01-19 抗原性インフルエンザ－フェリチンポリペプチド

Country Status (4)

Country Link
EP (1) EP3773703A1 (https=)
JP (2) JP2021519600A (https=)
CN (1) CN112512565A (https=)
WO (1) WO2019195284A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP4139331A4 (en) * 2020-04-22 2024-10-02 Aramis Biotechnologies Inc. SUPRASTRUCTURE WITH MODIFIED INFLUENZA HEMAGGLUTININ WITH REDUCED INTERACTION WITH SIALIC ACID
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
US20240165224A1 (en) * 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012225885A (ja) * 2011-04-22 2012-11-15 Nara Institute Of Science & Technology 被検物質の電気化学的検出方法
WO2013044203A2 (en) * 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
WO2015183969A1 (en) * 2014-05-27 2015-12-03 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
JP2016519658A (ja) * 2013-03-13 2016-07-07 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
EP2515112B1 (en) * 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
US9580475B2 (en) 2011-06-20 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
CA2868330A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
BR112018076015A8 (pt) 2016-06-17 2022-06-28 Sanofi Pasteur Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012225885A (ja) * 2011-04-22 2012-11-15 Nara Institute Of Science & Technology 被検物質の電気化学的検出方法
WO2013044203A2 (en) * 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
JP2016519658A (ja) * 2013-03-13 2016-07-07 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用
WO2015183969A1 (en) * 2014-05-27 2015-12-03 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEM. SOC. REV., vol. 45, JPN6023008985, 2016, pages 1691 - 1719, ISSN: 0005006603 *
J. MED. CHEM., vol. 42, JPN6023008988, 1999, pages 4640 - 4649, ISSN: 0005006601 *
JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 47, JPN6024008834, 1992, pages 161 - 174, ISSN: 0005273584 *
SCIENTIFIC REPORTS, vol. 6:36298, JPN6023008989, 2016, pages 1 - 11, ISSN: 0005006600 *
化学と生物, vol. 52, no. 4, JPN6023008986, 2014, pages 233 - 240, ISSN: 0005153856 *

Also Published As

Publication number Publication date
EP3773703A1 (en) 2021-02-17
CN112512565A (zh) 2021-03-16
WO2019195284A1 (en) 2019-10-10
JP2024041980A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
US20240216497A1 (en) Ferritin Proteins
US20250059240A1 (en) Antigenic Respiratory Syncytial Virus Polypeptides
JP2024041980A (ja) 抗原性インフルエンザ－フェリチンポリペプチド
US12121562B2 (en) Antigenic Epstein Barr virus polypeptides
US11993636B2 (en) Antigenic OspA polypeptides
JP5942296B2 (ja) 少なくとも１つのｃｘｘｃモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用
US20170189518A1 (en) Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
US20240092840A1 (en) Vaccine formulation comprising recombinant overlapping peptides and native proteins
RU2816208C2 (ru) АНТИГЕННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ ПОСЛЕДОВАТЕЛЬНОСТИ OspA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240308